Table 1.
Study Characteristics of Included Clinical Trials.
| Study ID | Clinical Trial No. | Country | Phase | Publication Type | Malignancy | Antigen Target |
|---|---|---|---|---|---|---|
| Annesley 2021 | NCT03330691 | USA | 1 | Abstract | ALL | CD19/CD22 |
| Baird 2021 | NCT04088890 | USA | 1 | Letter | LBCL | CD22 |
| Cao 2021 | ChiCTR-OPN-16009847 | China | 0 | Full Report | NHL | CD19/CD22 |
| Cordoba 2021 | NCT03289455 | UK | 1 | Full Report | ALL | CD19/CD22 |
| Dai 2020 | NCT03185494 | China | 1 | Full Report | ALL | CD19/CD22 |
| Frey 2021 | NCT03620058 | USA | 1 | Abstract | ALL | CD19/CD22 |
| Gardner 2020 | NCT03330691 | USA, Canada | 1 | Abstract | ALL | CD19/CD22 |
| Hu 2021 | NCT04227015 | China | 1 | Full Report | ALL | CD19/CD22 |
| Liu 2021 A | ChiCTR-ONC-17013648 | China | 1 | Full Report | ALL | CD19/CD22 |
| Liu 2021 B | NCT03614858 | China | 1/2 | Abstract | ALL | CD19/CD22 |
| Liu 2022 | ChiCTR1800014457 | China | 1 | Full Report | NHL | CD19/CD22/ CD20 |
| Pan 2019 | ChiCTR-OIC-17013523 | China | 1 | Full Report | ALL | CD22 |
| Pan 2020 | ChiCTR-OIB-17013670 | China | 1 | Letter | ALL | CD19/CD22 |
| Ramakrishnan 2020 | NCT03287817 | UK, USA | 1 | Abstract | DLBCL | CD19/CD22 |
| Schultz 2018 | NCT03241940 | USA | 1 | Abstract | ALL | CD19/CD22 |
| Shah 2020 | NCT02315612 | USA | 1 | Full Report | ALL | CD22 |
| Shalabi 2020 | NCT03448393 | USA | 1 | Abstract | ALL | CD19/CD22 |
| Singh 2021† | NCT02650414 and NCT02588456 | USA | 1 | Full Report | ALL | CD22 |
| Speigel 2021 | NCT03233854 | USA | 1 | Full Report | ALL, LBCL | CD19/CD22 |
| Summers 2021†† | NCT03244306 (V1) and NCT04571138 (V2) | USA | 1 | Abstract | ALL | CD22 |
| Tan 2021 | ChiCTR2000028793 | China | 1 | Letter | ALL | CD22 |
| Wang 2020 | ChiCTR-OPN-16008526 | China | 1 | Full Report | ALL, NHL | CD19/CD22 |
| Wang 2021 | ChiCTR2000032211 | China | 0 | Full Report | ALL | CD19/CD22 |
| Wei 2021 | ChiCTR1800015575 | China | 1 | Full Report | ALL, NHL | CD19/CD22 |
| Yang 2018 | NCT03312205 | China | 1 | Abstract | ALL | CD19/CD22 |
| Yang 2020 | NCT04129099 | China | 1 | Abstract | ALL | CD19/CD22 |
| Yang 2019 | NCT03825731 | China | 1 | Abstract | ALL | CD19/CD22 |
| Zhang 2021 A | NCT03196830 | China | 2 | Full Report | NHL | CD19/CD22 |
| Zhang 2021 B | NCT04539444 | China | 2 | Abstract | NHL | CD19/CD22 |
| Zhu 2021 | ChiCTR1800019298 | China | 1 | Full Report | ALL, DLBCL | CD22 |
ALL, acute lymphoblastic leukemia; NHL, Non-Hodgkin’s Lymphoma; LBCL, large B-cell lymphoma; DLBCL, diffuse large B-cell lymphoma. †Singh 2021 reports combined results of an adult and pediatric study investigating the same intervention. ††Summers 2021 reports results of an initial (V1) and optimized (V2) CAR construct.